Evidence map›Paper›PMID 27716121›Full record

ArticleBMC cancer2016

Leucine-rich diet alters the

Laís Rosa Viana, Rafael Canevarolo, Anna Caroline Perina Luiz, Raquel Frias Soares, Camila Lubaczeuski, Ana Carolina de Mattos Zeri, Maria Cristina Cintra Gomes-Marcondes

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 37 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Metabolomics-driven discovery of therapeutic targets for cancer cachexia.Journal of cachexia, sarcopenia and muscle · 2024
    Review
  5. Article
  6. Review
  7. Metabolomics and its Applications in Cancer Cachexia.Frontiers in molecular biosciences · 2022
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Serum and MuscleNutrients · 2020
    Article
  14. Article
  15. Metabolites · 2020
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Modulating Metabolism to Improve Cancer-Induced Muscle Wasting.Oxidative medicine and cellular longevity · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Laís Rosa VianaDepartment of Structural and Functional Biology, Laboratory of Nutrition and Cancer, Institute of Biology, University of Campinas-UNICAMP, Campinas, 13083862, São Paulo, Brazil.
Rafael CanevaroloBrazilian Biosciences National Laboratory, Campinas, São Paulo, Brazil.
Anna Caroline Perina LuizDepartment of Structural and Functional Biology, Laboratory of Nutrition and Cancer, Institute of Biology, University of Campinas-UNICAMP, Campinas, 13083862, São Paulo, Brazil.
Raquel Frias SoaresDepartment of Structural and Functional Biology, Laboratory of Nutrition and Cancer, Institute of Biology, University of Campinas-UNICAMP, Campinas, 13083862, São Paulo, Brazil.
Camila LubaczeuskiDepartment of Structural and Functional Biology, Laboratory of Nutrition and Cancer, Institute of Biology, University of Campinas-UNICAMP, Campinas, 13083862, São Paulo, Brazil.
Ana Carolina de Mattos ZeriBrazilian Biosciences National Laboratory, Campinas, São Paulo, Brazil.
Maria Cristina Cintra Gomes-MarcondesDepartment of Structural and Functional Biology, Laboratory of Nutrition and Cancer, Institute of Biology, University of Campinas-UNICAMP, Campinas, 13083862, São Paulo, Brazil. cintgoma@unicamp.br.
Universidade Estadual de Campinas (UNICAMP) · BRBrazilian Biosciences National Laboratory · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCachexia is one of the most important causes of cancer-related death. Supplementation with branched-chain amino acids, particularly leucine, has been used to minimise loss of muscle tissue, although few studies have examined the effect of this type of nutritional supplementation on the metabolism of the tumour-bearing host. Therefore, the present study evaluated whether a leucine-rich diet affects metabolomic derangements in serum and tumour tissues in tumour-bearing Walker-256 rats (providing an experimental model of cachexia).

methodsAfter 21 days feeding Wistar female rats a leucine-rich diet, distributed in L-leucine and LW-leucine Walker-256 tumour-bearing groups, we examined the metabolomic profile of serum and tumour tissue samples and compared them with samples from tumour-bearing rats fed a normal protein diet (C - control; W - tumour-bearing groups). We utilised

resultsAmong the 58 serum metabolites examined, we found that 12 were altered in the tumour-bearing group, reflecting an increase in activity of some metabolic pathways related to energy production, which diverted many nutrients toward tumour growth. Despite displaying increased tumour cell activity (i.e., higher Ki-67 and mTOR expression), there were no differences in tumour mass associated with changes in 23 metabolites (resulting from valine, leucine and isoleucine synthesis and degradation, and from the synthesis and degradation of ketone bodies) in the leucine-tumour group. This result suggests that the majority of nutrients were used for host maintenance.

conclusionA leucine rich-diet, largely used to prevent skeletal muscle loss, did not affect Walker 256 tumour growth and led to metabolomic alterations that may partially explain the positive effects of leucine for the whole tumour-bearing host.

Indexed as

AnimalsCachexiaCell Line, TumorDietFemaleLeucineMetabolomeNeoplasmsNeoplasm TransplantationRats, WistarTumor BurdenLeucineCancer cachexiaLeucine supplementationMetabolic derangementsMetabolomicWalker 256 tumour

Identifiers

PMID27716121
PMCPMC5048609
OpenAlexW2528623490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.